ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Heart disease"

  • Abstract Number: 1957 • ACR Convergence 2024

    Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study

    Aïcha Kante1, Andreea Afana2, Damien Sène3, Valérie Bousson4, Trecy Goncalves5, Edouard Ballout5, Solenn Toupin5, Jean-Guillaume Dillinger6, William Bigot3, Valentin Pagis7, Karine Champion3, Ruxandra burlacu7, stephane mouly3, Patrick Henry6, Theo Pezel6 and Cloé Comarmond3, 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 2Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, 3Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 4Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, 5Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, 6Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, 7Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 1958 • ACR Convergence 2024

    Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients

    Aïcha Kante1, Andreea Afana2, Damien Sène3, Karine Champion3, Valentin Pagis4, William Bigot3, Véronique Delcey5, Amanda Lopes3, Abdellatif Tazi6, Blanca Amador Borrero4, Bruno Crestani7, Claire Baladi8, Valérie Bousson9, Trecy Goncalves10, Edouard Ballout10, Solenn Toupin10, stephane mouly3, Jean-Guillaume Dillinger11, Patrick Henry11, Theo Pezel11 and Cloé Comarmond3, 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 2Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, 3Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 4Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, 5Department of Infectious diseases, Lariboisère University Hospital, Paris, Ile-de-France, France, 6National Reference Center for Histiocytoses, Department of Pulmonology, AP-HP, Saint-Louis Hospital, Paris, France, 7National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, 8Université d’Angers, Department of Cardiology, University Hospital of Angers, Angers, France, 9Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, 10Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, 11Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Cardiac sarcoidosis (CS) is an underdiagnosed condition characterized by the formation of non-caseating granuloma in the myocardium, potentially leading to arrhythmia, acute heart failure,…
  • Abstract Number: 0347 • ACR Convergence 2024

    Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades

    Elizabeth Matz1 and Ram Singh2, 1UCLA David Geffen School of Medicine, Los Angeles, 2UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…
  • Abstract Number: 2009 • ACR Convergence 2024

    Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes

    Amara Sarwal1, Augustine Takyi1, Guo Wei1, McKenna Nevers1, Ravinder Singh1, Sydney Hartsell1, Robert Boucher1, Niharika Katkam1, Akhil Chakravartula1, Jincheng Shen1, Srinivasan Beddhu1 and Naomi Schlesinger2, 1University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
  • Abstract Number: 0472 • ACR Convergence 2024

    Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis

    Bas Dijkshoorn1, Sreen Mohamed2, Romy Hansildaar2, Henk Everaars3, Geoffrey Mooij3, Luuk Hopman3, Paul Knaapen3, Lourens Robbers3 and Michael Nurmohamed4, 1Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 2Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, 3Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, 4Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
  • Abstract Number: 2026 • ACR Convergence 2024

    Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus

    Rebeca L. Polina-Lugo1, Aleydis Gonzalez Melendez1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Annette Dominguez-Guerra3, Victoria P. Limas-Martínez1, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
  • Abstract Number: 0556 • ACR Convergence 2024

    Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis

    Asier García-Alija1, Hye Sang Park1, Patricia Moya1, Ana Laiz1, Carla Marco2, Albert Casals1, Concepcion Pitarch2, Cesar Diaz-Torné1, Berta Paula Magallares3, Ivan Castellvi Barranco1, Susana Fernández-Sánchez1, Andrea García-Guillen2, Jose Luis Tandaipan1, Helena Codes-Mendez1, Guillem Verdaguer1, Luis Sainz1 and Hèctor Corominas1, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital Dos de Maig, Barcelona, Spain, 3Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain

    Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…
  • Abstract Number: 2046 • ACR Convergence 2024

    Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents

    Antonio Brucato1, Elisa Ceriani2, Francesco Agozzino3, Silvia Berra4, Antonio Gidaro2, Silvia Macchi5, Letizia Vena5, Paolo Bindi5, Alberto Pavarani6, Francesco Moda7, Ludovico Luca Sicignano8, Celeste Murace8, Elena Verrecchia8, Caterina Chiara Decarlini9, Silvia Maestroni10, Gabriella Marinaro4, Lucia Trotta3, Massimo Pancrazi3, Lisa Serati3, Enrica Negro3, Claudia Gabiati3, Elisa Calabrò3, Angela Mauro11, Luisa Carrozzo3, Emanuele Bizzi3 and Massimo Imazio12, 1Department of Biomedical and Clinical Sciences, University of Milano, Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Lombardia, Italy, 2Department of Internal Medicine, Ospedale Luigi Sacco, Milano, Milan, Italy, 3Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milan, Italy, 4Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Italy, 5University of Milano, Milan, Italy, 6University of Milano, Milan, 7Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 8Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Rome, Italy, 9Cardiology Division, Cardiovascular Department, San L. Mandic Hospital, Merate, Lecco, Italy, 10Internal Medicine Department, Papa Giovanni XXIII Hospital, Bergamo, Bergamo, Italy, 11Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy, 12University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Milan, Italy

    Background/Purpose: Recurrent pericarditis (RP) challenges pts and clinicians in terms of long-term management. Objective of this study was to evaluate the remission rate (drug-free for…
  • Abstract Number: 1469 • ACR Convergence 2023

    Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus

    Daniel Joyce1, Jeffrey. Berger2, Allison Guttmann3, Ghadeer Hasan4, Jill Buyon5, H Michael Belmont1, Jane Salmon6, Anca Askanase7, Joan Bathon8, Laura Geraldino-Pardilla9, Yousaf Ali10, Ellen Ginzler11, Chaim Putterman12, Caroline Gordon13, Charles Helmick14, Kamil Barbour15, Heather Gold16, Hilary Parton17 and Peter Izmirly2, 1NYU School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3Atlantic Health System, Summit, NJ, 4Optum, Jersey City, NJ, 5NYU Grossman School of Medicine, New York, NY, 6Hospital for Special Surgery, New York, NY, 7Columbia University Medical Center, New York, NY, 8Columbia University, New York, NY, 9Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, 10Icahn School of Medicine at Mount Sinai, New York, NY, 11SUNY Downstate Health Sciences University, Brooklyn, NY, 12Albert Einstein College of Medicine, Bronx, NY, 13Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 14NA, Atlanta, GA, 15Centers for Disease Control and Prevention, Atlanta, GA, 16New York University, New York, NY, 17New York City Department of Health and Mental Hygiene, Queens, NY

    Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…
  • Abstract Number: 1486 • ACR Convergence 2023

    Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)

    Hamza Liaqat1, Muhammad Qureshi2, Awais Farooq3, Mashal Awais2, Amar Patel4 and Aisha Barlas5, 1Wah Medical College, Wah Cantt, Pakistan, 2Southeast Health Internal Medicine Residency Prog., Dothan, AL, 3University of Illinois Chicago, Chicago, IL, 4Texas Tech University Health Sciences Center, El paso, TX, 5Mercy Health, Rockford, IL

    Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
  • Abstract Number: 1620 • ACR Convergence 2023

    Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

    Ye Liu1, Tarun Arora2, S. Bobo Tanner3 and Jeffrey Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
  • Abstract Number: 1728 • ACR Convergence 2023

    A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

    Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
  • Abstract Number: 1799 • ACR Convergence 2023

    Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain

    Elizabeth Park1, Laura Daniel2, Alyson Dickson3, Meghan Corriere4, Puran Nepal5, Kathi Hall4, Dale Plummer4, William Dupont4, Katherine Murray4, C. Michael Stein3, Wayne Ray4 and Cecilia Chung6, 1Columbia University Irving Medical Center, New York, NY, 2University of Miami, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Vanderbilt University, Nashville, TN, 5University of Miami Health System and Miller School of Medicine, Miami, FL, 6University of Miami, Miami, FL

    Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…
  • Abstract Number: 2096 • ACR Convergence 2023

    Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure

    Elizabeth Park1, Kazato Ito2, Christopher Depender1, Jon Giles3 and Joan Bathon3, 1Columbia University Irving Medical Center, New York, NY, 2Columbia University Medical Center, New York, NY, 3Columbia University, New York, NY

    Background/Purpose: Elevated left ventricular (LV) mass (LVM) is an important precursor to clinical heart failure (HF) in the general population. In fact, rheumatoid arthritis (RA)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology